PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). METHODS: Patients ≥18 years of age...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Thorac Oncol
Prif Awduron: Zinner, Ralph G., Obasaju, Coleman K., Spigel, David R., Weaver, Robert W., Beck, J. Thaddeus, Waterhouse, David M., Modiano, Manuel R., Hrinczenko, Borys, Nikolinakos, Petros G., Liu, Jingyi, Koustenis, Andrew G., Winfree, Katherine B., Melemed, Symantha A., Guba, Susan C., Ortuzar, Waldo I., Desaiah, Durisala, Treat, Joseph A., Govindan, Ramaswamy, Ross, Helen J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4276572/
https://ncbi.nlm.nih.gov/pubmed/25371077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000366
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg